openPR Logo
Press release

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

05-14-2024 09:42 PM CET | Health & Medicine

Press release from: ABNewswire

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs,

DelveInsight's, "Diabetic Retinopathy Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Diabetic Retinopathy Pipeline Report

* DelveInsight's Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
* The leading companies working in the Diabetic Retinopathy Market include Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
* Promising Diabetic Retinopathy Pipeline Therapies in the various stages of development include Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
* March 2024:- Digital Diagnostics Inc.- Diabetes affects 30.3 million people or 9.3% of the population of the United States. Results of a study by the Eye Diseases Prevalence Research Group reveal that 40% of diabetes patients have some degree of diabetic retinopathy (DR) and that as many as 8% have severe, vision-threatening forms of DR.

Request a sample and discover the recent advances in Diabetic Retinopathy Treatment Drugs @ Diabetic Retinopathy Pipeline Report [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

In the Diabetic Retinopathy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Diabetic Retinopathy Overview

Diabetic retinopathy (DR) is a major complication of diabetes mellitus (DM), which remains a leading cause of visual loss in working-age populations. The retina contains photoreceptor cells that function in the process of visual transduction, i.e., transforming light signals to nerve impulses eventually transmitted from the optic nerve to the brain forming an image.

Find out more about Diabetic Retinopathy Therapeutics Assessment @ Diabetic Retinopathy Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Retinopathy Emerging Drugs Profile

* KSI-301: Kodiak Sciences
* Brolucizumab: Novartis
* RGX 314: Regenxbio Inc.
* OTT-166: OcuTerra Therapeutics
* OTX-TKI: Ocular Therapeutix

Diabetic Retinopathy Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Diabetic Retinopathy therapies. The Diabetic Retinopathy companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. phase III include, Kodiak Sciences.

DelveInsight's Diabetic Retinopathy pipeline report covers around 55+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Learn more about the emerging Diabetic Retinopathy Pipeline Therapies @ Diabetic Retinopathy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Diabetic Retinopathy Pipeline Report

* Coverage- Global
* Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
* Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.

Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Diabetic Retinopathy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Diabetic Retinopathy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* KSI-301: Kodiak Sciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* RGX 314: Regenxbio Inc
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* OTX-TKI: Ocular Therapeutix
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Diabetic Retinopathy Key Companies
* Diabetic Retinopathy Key Products
* Diabetic Retinopathy- Unmet Needs
* Diabetic Retinopathy- Market Drivers and Barriers
* Diabetic Retinopathy- Future Perspectives and Conclusion
* Diabetic Retinopathy Analyst Views
* Diabetic Retinopathy Key Companies
* Appendix

For further information on the Diabetic Retinopathy Pipeline therapeutics, reach out to Diabetic Retinopathy Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-retinopathy-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) here

News-ID: 3496500 • Views:

More Releases from ABNewswire

IntegriCom Wins Best of Gwinnett 2025 Award for Excellence in IT Services
IntegriCom Wins Best of Gwinnett 2025 Award for Excellence in IT Services
IntegriCom of Suwanee, GA has been named a Best of Gwinnett 2025 winner, recognizing its reliable, innovative IT solutions and strong client support across Gwinnett and the greater Atlanta business community. The company delivers managed IT, cybersecurity, cloud services, and strategic technology planning, providing proactive monitoring, help desk support, and compliance guidance to improve uptime, security, and operational efficiency for growing organizations. Suwanee, GA - February 16, 2026 - IntegriCom proudly
Las Vegas Physician Dr. Wallace Brucker Pioneers Executive Concierge Medicine Movement as Corporate America Embraces Biological Performance Optimization
02-16-2026 | Sports
ABNewswire
Las Vegas Physician Dr. Wallace Brucker Pioneers Executive Concierge Medicine Mo …
Former Special Forces Physician Leads Revolutionary Approach to Executive Health, Addressing Critical Gap Between Standard Healthcare and High-Performance Demands LAS VEGAS, NV - February 16, 2026 - As corporate America grapples with unprecedented leadership demands in an increasingly complex business environment, a revolutionary healthcare approach is transforming how companies support their most valuable executives. Dr. Wallace Brucker, MD, Medical Director of LV Longevity Lab, has emerged as a pioneering leader in
UVMC Donation Helps Expand Edison State Nursing Wing in Piqua
UVMC Donation Helps Expand Edison State Nursing Wing in Piqua
Edison State Community College in Piqua, Ohio, received a donation from the UVMC Community Benefit Fund to support a new nursing wing, named the Upper Valley Medical Center/Premier Health Nursing Wing Addition. The expansion will add classrooms and simulation space, strengthen associate and BSN programs, and prepare more nurses for the Miami Valley. The Foundation has raised $4.1M of the $4.5M goal, with construction planned for August 2026 and opening
When Convenience Comes at a Cost: Drivers Reconsider the Price of Past Car Finance Deals
When Convenience Comes at a Cost: Drivers Reconsider the Price of Past Car Finan …
What once felt like a convenient way to finance a car is now under closer review. Across the UK, drivers are taking a second look at old agreements to check for signs of mis-sold car finance. Reclaim247 is helping people explore potential car finance claims and PCP claims using a fast, document-free tool with no cost to begin. Manchester, UK - February 16, 2026 - For years, car finance was sold

All 5 Releases


More Releases for Diabetic

Exploring The Diabetic Retinopathy Market In A Diabetic-Prevalent World: The Dri …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Diabetic Retinopathy Market Size Growth Forecast: What to Expect by 2025? The diabetic retinopathy market has experienced robust expansion over the last few years, with projections indicating a rise from $8.61 billion in 2024 next year to $9.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report. On the basis of
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282 Global Diabetic Socks Market: Factors Impacting the Market The primary factors driving the growth of the global diabetic socks market are increasing
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be